^
Association details:
| Biomarker: | STK11 deletion + KRAS mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Impact of STK11 and/or KEAP1 Deletion on Outcomes to Immunotherapy in Non-Small Cell Lung Cancer
Published date:
01/28/2023
Excerpt:
...we identified 717 patients with advanced non-squamous NSCLC who received ICI monotherapy…in KRASMUT NSCLC, STK11DEL was associated with a numerically lower overall response rate (ORR) (13.6% vs. 32.3%, p=0.09), a significantly shorter progression-free survival (PFS) (HR 1.8, p=0.01), and a numerically shorter OS (HR 1.5, p=0.14). There was no association between STK11DEL and ICI outcomes in KRASWT NSCLC....STK11 and KEAP1 deletion may be linked to generally worse outcomes to ICI in KRASMUT NSCLC.
